文献速递产科

黄体酮治疗先兆流产女性(STOP试验):一项安慰剂对照随机临床试验

Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial.
PubMed 文献 · Hum Reprod · 2023-01-01

该随机双盲安慰剂对照试验在澳大利亚一家三级产科中心纳入278名孕10周内阴道出血的先兆流产女性,比较阴道黄体酮400 mg每晚用至孕12周与安慰剂的活产率。因无效性中期分析提前终止,活产率两组无显著差异(82.4% vs 84.2%,RR 0.98,95%CI 0.88-1.09,P=0.683)。作者认为不应常规使用黄体酮治疗先兆流产,既往流产史者的疗效需进一步研究。

要点

  • 阴道黄体酮400 mg每晚用至孕12周未提高先兆流产女性的活产率。
  • 活产率黄体酮组82.4%(112/136) vs 安慰剂组84.2%(112/133),RR 0.98,95%CI 0.88-1.09,P=0.683。
  • 作者认为该情形不应常规使用黄体酮,既往流产史者的疗效需进一步研究。

核心结论

  • 在先兆流产女性中,阴道黄体酮400 mg每晚用至孕12周未提高活产率,作者认为不应常规用于先兆流产,既往流产后的疗效需进一步研究。

研究设计与样本

  • 随机双盲安慰剂对照试验,2012年2月至2019年4月在澳大利亚南布里斯班一家三级产科中心Mater Mothers' Hospital进行。
  • 纳入孕10周内阴道出血的先兆流产孕妇,按1:1随机分为阴道黄体酮400 mg组与安慰剂组,均用至孕12周,主要终点为活产。
  • 计划随机386名(每组193名),实际随机278名后因无效性中期分析提前终止;黄体酮组139名、安慰剂组139名,主要结局数据分别有136名和133名。

主要发现

  • 活产率黄体酮组82.4%(112/136) vs 安慰剂组84.2%(112/133),RR 0.98,95%CI 0.88-1.09;风险差-0.02,95%CI -0.11-0.07;P=0.683。
  • 至少一次既往流产者中,活产率黄体酮组80.6%(54/67) vs 安慰剂组84.4%(65/77),RR 0.95,95%CI 0.82-1.11,P=0.550。
  • 两次既往流产者中黄体酮未见显著效果(RR 1.28,95%CI 0.96-1.72,P=0.096),两次以上者亦未见显著效果(RR 0.79,95%CI 0.53-1.19,P=0.267)。
  • 早产率黄体酮组12.9% vs 安慰剂组9.3%(RR 1.38,95%CI 0.69-2.78,P=0.361);出生体重中位数3310 g vs 3300 g(P=0.992)。
  • 其他产科和围产结局亦无显著差异。

临床怎么用

  • 作者结论认为,未发现证据支持阴道黄体酮对先兆流产女性的治疗效果,该情形不应常规使用黄体酮。
  • 作者指出,先兆流产女性既往流产后黄体酮的治疗效果需进一步研究。

局限性

  • 研究为单中心。
  • 因中期分析提前终止,未达到计划样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: In women with threatened miscarriage, does progesterone supplementation until the completion of the first trimester of pregnancy increase the probability of live birth? SUMMARY ANSWER: In women with threatened miscarriage, 400 mg vaginal progesterone nightly, from onset of bleeding until 12 weeks, did not increase live birth rates. WHAT IS KNOWN ALREADY: Limited evidence has indicated that vaginal micronized progesterone may make little or no difference to the live birth rate when compared with placebo in women with threatened miscarriage. Subgroup analysis of one recent randomized trial reported that in women with bleeding and at least one previous miscarriage, progesterone might be of benefit. STUDY DESIGN, SIZE, DURATION: We performed a randomized, double-blinded, placebo-controlled trial between February 2012 and April 2019. Eligible pregnant women under 10 weeks gestation, experiencing a threatened miscarriage as apparent from vaginal bleeding were randomized into two groups in a 1:1 ratio: the intervention group received 400 mg progesterone as vaginal pessaries, the control group received placebo vaginal pessaries, both until 12 weeks gestation. The primary endpoint was live birth. We planned to randomize 386 women (193 per group). The study was stopped at a planned interim analysis for futility after randomization of 278 women. PARTICIPANTS/MATERIALS, SETTING, METHODS: This trial was conducted at the Mater Mothers' Hospital, a tertiary centre for maternity care in South Brisbane, Queensland, Australia. We randomized 139 women to the intervention group and 139 women to the placebo group. Primary outcome data were available for 136 women in the intervention group and 133 women in the placebo group. MAIN RESULTS AND THE ROLE OF CHANCE: The live birth rates were 82.4% (112/136) and 84.2% (112/133) in the intervention group and placebo group, respectively (risk ratio (RR) 0.98, 95% CI 0.88 to 1.09; risk difference -0.02, 95% CI -0.11 to 0.07; P = 0.683). Among women with at least one previous miscarriage, live birth rates were 80.6% (54/67) and 84.4% (65/77) (RR 0.95, 95% CI 0.82-1.11; P = 0.550). No significant effect was seen from progesterone in women with two (RR 1.28, 95% CI 0.96-1.72; P = 0.096) or more (RR 0.79, 95% CI 0.53-1.19; P = 0.267) previous miscarriages. Preterm birth rates were 12.9% and 9.3%, respectively (RR 1.38; 95% CI 0.69 to 2.78; P = 0.361). Median birth weight was 3310 vs 3300 g (P = 0.992). There were also no other significant differences in obstetric and perinatal outcomes. LIMITATIONS, REASONS FOR CAUTION: Our study was single centre and did not reach the planned sample size because it was stopped prematurely at an interim analysis. WIDER IMPLICATIONS OF THE FINDINGS: We did not find evidence supporting the treatment effect of vaginal progesterone in women with threatened miscarriage. Progesterone in this setting should not be routinely used for threatened miscarriage. The treatment effect in women with threatened miscarriage after previous miscarriages warrants further research. STUDY FUNDING/COMPETING INTEREST(S): Mothers' and babies Golden Casket Clinical Fellowship (L.A.M.). Progesterone and placebo pessaries were provided by Perrigo Australia.B.W.J.M. reports grants from NHMRC, personal fees from ObsEva, personal fees from Merck KGaA, personal fees from Guerbet, personal fees from iGenomix, outside the submitted work. TRIAL REGISTRATION NUMBER: ACTRN12611000405910. TRIAL REGISTRATION DATE: 19 April 2011. DATE OF FIRST PATIENT’S ENROLMENT: 06 February 2012.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. McLindon LA, James G, Beckmann MM, et al. Progesterone for women with threatened miscarriage (STOP trial): a placebo-controlled randomized clinical trial. Hum Reprod. 2023. PMID: 36806843. doi:10.1093/humrep/dead029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。